<DOC>
	<DOCNO>NCT02621164</DOCNO>
	<brief_summary>This study multi-center , randomize , double-blind Phase III clinical trial . The aim study describe immunogenicity safety quadrivalent cell culture-derived influenza vaccine compare trivalent egg-derived influenza vaccine among subject .</brief_summary>
	<brief_title>Immunogenicity Safety Quadrivalent Influenza Vaccine Children Adolescents</brief_title>
	<detailed_description>Subjects randomly assign 4:1 ratio NBP607-QIV versus Agrippal S1 . To assess immunogenicity , antibody level evaluate hemagglutination inhibition ( HI ) assay serum obtain pre-vaccination 28 day post-vaccination . To assess safety , solicited adverse event 7 day post-vaccination unsolicited adverse event 28 day post-vaccination assess report . The serious adverse event collect 6 month post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children adolescent age 6 month 18 year . Those born normal pregnancy period ( 37 week ) age 6 month &lt; 1 year Those whose legally acceptable representative give write consent participate study comply study requirement . Subjects hypersensitive component vaccine , i.e. , egg , chicken chicken product . Subjects immune deficiency disorder malignant cancer . History GuillainBarre syndrome . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Subjects experience fever within 72 hour vaccination febrile disease ( exceed 38.0â„ƒ ) screening day . Subjects receive immunosuppressant immunemodifying drug within 3 month screen . Subjects receive blood product immunoglobulin within 3 month screen . Subjects receive influenza vaccination within 6 month prior screen . Subjects receive vaccination within month . screening , another vaccination schedule within month study vaccination . Subjects participate clinical trial within 4 week prior study vaccination . Subjects clinically significant chronic disease . Pregnant woman , breastfeed woman . Any condition , opinion Investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>